Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
18 Years
N/A
Female
Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Trial Information
Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Addition of HIPEC to the standard first line treatment of ovarian carcinoma.
Inclusion Criteria:
- stage III or only pleural stage IV ovarian carcinoma first line treatment
Exclusion Criteria:
- incomplete surgery poor performance status bad general condition
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
mortality rate
Outcome Description:
We will record the mortality rate of our interventions: 3 cycles of pre-operative chemotherapy, surgery and HIPEC, 3 cycles of post-operative chemotherapy.
Outcome Time Frame:
24 weeks
Safety Issue:
Yes
Principal Investigator
Joseph Kerger, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Institut Jules Bordet, Brussels, Belgium.
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
HIPEC
NCT ID:
NCT01709487
Start Date:
May 2010
Completion Date:
May 2014
Related Keywords:
- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- HIPEC
- ovarian carcinoma
- Bordet
- Carcinoma
- Ovarian Neoplasms
- Neoplasms, Glandular and Epithelial
- Fallopian Tube Neoplasms
Name | Location |
|---|
